se of Tocilizumab in the inflammatory phase of COVID-19 / new coronavirus disease

Phase 1

• Conditions: COVID-19 / new coronavirus disease; MedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: EUCTR2020-002039-31-FI
• Lead Sponsor: Turku University Hospitla

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-28
• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

age > 18 years / hospitalized with COVID-19 / SpO2 Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 45
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 45

Exclusion Criteria

allergy to monoclonals / active tbc or obvious bact infection / long-term anti-rejection or immunomodul drugs / pregnant or lactating woman / participating in other drug clinical trials

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified